CoChat
Sign Up
Cited by 204SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 epidemiological studies

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Open access
Tenforde, Mark W., Self, Wesley H., Naioti, Eric A., Ginde, Adit A., Douin, David J., Olson, Samantha M., Talbot, H. Keipp, Casey, Jonathan D. +150 more·2021·MMWR. Morbidity and Mortality Weekly Report
DOI 10.15585/mmwr.mm7034e2PMC PMC8389395
Open this paper in CoChat — free accountOpen PDF

Abstract

Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability of protection. In an evaluation at 21 hospitals in 18 states, the duration of mRNA vaccine (Pfizer-BioNTech or Moderna) effectiveness (VE) against COVID-19-associated hospitalizations was assessed among adults aged ≥18 years. Among 3,089 hospitalized adults (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), the median age was 59 years, 48.7% were female, and 21.1% had an immunocompromising condition. Overall, 141 (11.8%) case-patients and 988 (52.1%) controls were fully vaccinated (defined as receipt of the second dose of Pfizer-BioNTech or Moderna mRNA COVID-19 vaccines ≥14 days before illness onset), with a median interval of 65 days (range = 14-166 days) after receipt of second dose. VE against COVID-19-associated hospitalization during the full surveillance period was 86% (95% confidence interval [CI] = 82%-88%) overall and 90% (95% CI = 87%-92%) among adults without immunocompromising conditions. VE against COVID-19- associated hospitalization was 86% (95% CI = 82%-90%) 2-12 weeks and 84% (95% CI = 77%-90%) 13-24 weeks from receipt of the second vaccine dose, with no significant change between these periods (p = 0.854). Whole genome sequencing of 454 case-patient specimens found that 242 (53.3%) belonged to the B.1.1.7 (Alpha) lineage and 74 (16.3%) to the B.1.617.2 (Delta) lineage. Effectiveness of mRNA vaccines against COVID-19-associated hospitalization was sustained over a 24-week period, including among groups at higher risk for severe COVID-19; ongoing monitoring is needed as new SARS-CoV-2 variants emerge. To reduce their risk for hospitalization, all eligible persons should be offered COVID-19 vaccination.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15585/mmwr.mm7034e2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [4]Tenforde MW, Patel MM, Ginde AA, Effectiveness of SARS-CoV-2 mRNA vaccines for preventing Covid-19 hospitalizations in the United States. Clin Infect Dis. In press 2021.

Cited by

Sorted by citations

Related

Authors
Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., Ghamande, S., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Gong, M. N., Mohamed, A., Henning, D. J., Steingrub, J. S., Peltan, I. D., Brown, S. M., Martin, E. T., Monto, A. S., Khan, A., Hough, C. L., Busse, L. W., ten Lohuis, C. C., Duggal, A., Wilson, J. G., Gordon, A. J., Qadir, N., Chang, S. Y., Mallow, C., Rivas, C., Babcock, H. M., Kwon, J. H., Exline, M. C., Halasa, N., Chappell, J. D., Lauring, A. S., Grijalva, C. G., Rice, T. W., Jones, I. D., Stubblefield, W. B., Baughman, A., Womack, K. N., Lindsell, C. J., Hart, K. W., Zhu, Y., Stephenson, M., Schrag, S. J., Kobayashi, M., Verani, J. R., Patel, M. M., IVY Network Investigators, IVY Network, Calhoun, N., Murthy, K., Herrick, J., McKillop, A., Hoffman, E., Zayed, M., Smith, M., Settele, N., Ettlinger, J., Priest, E., Thomas, J., Arroliga, A., Beeram, M., Kindle, R., Kozikowski, L.-A., De Souza, L., Ouellette, S., Thornton-Thompson, S., Tyler, P., Mehkri, O., Ashok, K., Gole, S., King, A., Poynter, B., Stanley, N., Hendrickson, A., Maruggi, E., Scharber, T., Jorgensen, J., Bowers, R., King, J., Aston, V., Armbruster, B., Rothman, R. E., Nair, R., Chen, J.-T. (., Karow, S., Robart, E., Maldonado, P. N., Khan, M., So, P., Levitt, J., Perez, C., Visweswaran, A., Roque, J., Rivera, A., Frankel, T., Howell, M., Friedel, J., Goff, J., Huynh, D., Tozier, M., Driver, C., Carricato, M., Foster, A., Nassar, P., Stout, L., Sibenaller, Z., Walter, A., Mares, J., Olson, L., Clinansmith, B., Rivas, C., Gershengorn, H., McSpadden, E., Truscon, R., Kaniclides, A., Thomas, L., Bielak, R., Valvano, W. D., Fong, R., Fitzsimmons, W. J., Blair, C., Valesano, A. L., Gilbert, J., Crider, C. D., Steinbock, K. A., Paulson, T. C., Anderson, L. A., Kampe, C., Johnson, J., McHenry, R., Blair, M., Conway, D., LaRose, M., Landreth, L., Hicks, M., Parks, L., Bongu, J., McDonald, D., Cass, C., Seiler, S., Park, D., Hink, T., Wallace, M., Burnham, C.-A., & Arter, O. G.
Affiliations
  • Montefiore Medical Center (US)
  • Beth Israel Deaconess Medical Center (US)
  • Baylor Scott & White Health (US)
  • Baystate Medical Center (US)
  • Cleveland Clinic (US)
  • Emory University (US)
  • Hennepin County Medical Center (US)
  • Intermountain Medical Center (US)
  • Johns Hopkins University (US)
  • The Ohio State University (US)
  • Stanford University (US)
  • University of California, Los Angeles (US)
  • University of Colorado Hospital (US)
  • University of Iowa (US)
  • University of Miami (US)
  • University of Michigan (US)
  • University of Washington (US)
  • Vanderbilt University Medical Center (US)
  • Wake Forest University (US)
  • Washington University in St. Louis (US)
Corresponding author
Tenforde, Mark W.
ORCID
Venue
MMWR. Morbidity and Mortality Weekly Report
Publisher
Centers for Disease Control MMWR Office
Published
2021-08-27
Volume
70
Issue
34
Pages
1156-1162
ISSN
  • 0149-2195 (ISSN-L)
  • 1545-861X
DOI
10.15585/mmwr.mm7034e2
PMC
PMC8389395
OpenAlex
W3195990721
Cited by
204
References
8
Citations by year
2026: 1 · 2025: 10 · 2024: 22 · 2023: 43 · 2022: 86 · 2021: 42
FWCI
15.28
Type
journal article
Language
en
Open access
Locations
  • MMWR Morbidity and Mortality Weekly Report (publishedVersion)
  • PubMed Central (publishedVersion, public-domain)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • U.S. Department of Defense
  • Pfizer
  • Sanofi
  • Vanderbilt University
  • University of Miami
  • Brigham Young University
  • Ohio State University
  • Emory University
  • Medpace
  • United Therapeutics Corporation
  • Wake Forest University
  • Cleveland Clinic
  • University of Washington
  • Johns Hopkins University
  • Hennepin County Medical Center
  • Cumberland Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Vanderbilt University Medical Center
  • Incyte
  • Marcus Foundation
  • University of Oxford
  • Seqirus
  • National Institutes of Health
  • Agency for Healthcare Research and Quality
  • University of California, Los Angeles
  • National Heart, Lung, and Blood Institute (T32HL087738)
  • National Institute of General Medical Sciences (T32GM135169)
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
mRNA vaccines, BNT162b2, Moderna vaccine, COVID-19 pandemic, vaccine effectiveness, hospitalization, immunocompromising conditions, SARS-CoV-2 variants, hospitalized adults, real-world effectiveness, whole genome sequencing
MeSH terms
COVID-19, COVID-19 Vaccines, mRNA Vaccines, Adolescent, Adult, Aged, Female, Hospitalization, Humans, Male, Middle Aged, Time Factors, United States, Vaccination, Vaccines, Synthetic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review